More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings (+390.0% Growth)
- Ratings (3.3 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (11/9/15 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements 119.66M
Licensing and royalty revenue 770K
Total revenue 120.43M
Research and development
General and administrative 7.78M
Total operating expenses 75.78M
Loss from operations 44.65M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
Investment income 917K
Interest expense -9.13M
Gain (loss) on investments, net 1K
Loss before income tax expense
Income tax expense -789K
Net loss 35.65M
Basic net loss (in dollars per share) 0.3
Diluted net loss (in dollars per share) 0.29
Shares used in computing basic net loss per share (in shares) 119.74M
Shares used in computing diluted net loss per share (in shares) 127.78M